SRPT - Sarepta Therapeutics, Inc.
| Previous close | 153.69 |
| Open | 156.50 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's range | 149.08 - 157.65 |
| 52-week range | 32.36 - 176.50 |
| Volume | 2,339,255 |
| Avg. volume | 1,581,162 |
| Market cap | 9.807B |
| Beta | 1.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 17 Jul 2018 - 23 Jul 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 172.18 |
- Motley Fool•19 hours ago
Is Sarepta Therapeutics Stock Headed to Over $200 a Share?
Wall Street thinks Sarepta Therapeutics is still a bargain even after its shares have more than doubled in value this year.
- Investor's Business Daily•2 days ago
This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior'
Solid Biosciences plunged Wednesday on high volume after rival Sarepta Therapeutics reported strong data for its Duchenne muscular dystrophy treatment.
- Zacks•2 days ago
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
- MarketWatch•2 days ago
Sarepta shares rocket 40% on promising early results for DMD gene therapy
Sarepta Therapeutics Inc. shares skyrocketed 37.8% in Tuesday trade after the company released promising early results from a gene therapy program being developed for the rare degenerative disease Duchenne muscular dystrophy. Tuesday marked the stock’s second-largest percentage gain in over 20 years. Its largest-ever percentage gain came in September 2016, when Sarepta’s (SRPT) first drug was approved by the Food and Drug Administration.
- Zacks•2 days ago
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
- Zacks•2 days ago
Sarepta's Stock Soars on Encouraging Gene Therapy Results
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
- The Wall Street Journal•2 days ago
[$$] Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatment
Sarepta Therapeutics Inc. gained about $2.5 billion of stock market value Tuesday after an early stage trial of a gene therapy showed promise in its ability to treat patients with Duchenne muscular dystrophy. Sarepta said study results showed the therapy helped patients with the crippling disease significantly reduce levels of creatine kinase, an enzyme associated with muscle damage caused by the disorder. Results also showed patients receiving the treatment had robust levels of a protein key to muscle function.
CNBC•2 days agoMore tests are needed to develop a gene therapy for a rare genetic disease: Sarepta CEO
More tests are needed to develop a gene therapy for a rare genetic disease, says Sarepta Therapeutics CEO.
- Motley Fool•2 days ago
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Welcome to biotech investing.
- Motley Fool•2 days ago
What Happened in the Stock Market Today
On a day indexes fell due to worries over a trade war with China, Boeing was one of the stocks hardest hit on those concerns. Elsewhere, Sarepta Therapeutics jumped following positive trial results.
- Barrons.com•2 days ago
[$$] Sarepta Shares Up 37% on Gene Therapy Results
Sarepta Therapeutics’ impressive report today about an early-stage clinical trial for a gene therapy for Duchenne muscular dystrophy, or DMD, has powered its shares and raised hopes that the treatment could save the lives of children afflicted with what has been a fatal disease. Sarepta shares (SRPT) closed Tuesday up 37%, or $38.69, to $143.93, after the company said that its gene therapy had produced an average of 38.2% of the normal level of microdystrophin—a form of dystrophin, the muscle protein that is missing in boys with DMD. The results were unprecedented and showed a much higher level of protein expression than what we had expected,” says Liisa Bayko, an analyst at JMP who has an Outperform rating on the stock.
- Investor's Business Daily•2 days ago
Sarepta Gets 'Rousing Applause' And Rockets On Gene Therapy
Sarepta Therapeutics rocketed by more than half Tuesday after it presented early data for its gene therapy as a treatment for Duchenne muscular dystrophy.
- Motley Fool•2 days ago
Why Sarepta Therapeutics Stock Is Blasting Higher Today
Sarepta's experimental gene therapy could be a game-changer for patients with Duchenne muscular dystrophy.
Business Insider UK•3 days agoSarepta Therapeutics spikes 57% after a key trial shows its experimental gene therapy worked in 3 patients (SRPT, SLDB)
Sarepta Therapeutics was up more than 57% Tuesday morning after a key trial showed its experimental gene therapy worked in three patients. Follow Sarepta Therapeutics in real time here. Sarepta on Tuesday announced positive results for an early trial of three patients with duchenne muscular dystrophy who were given a gene therapy. After receiving the therapy, three boys, under the age of six, saw an increase in the protein.
Business Insider UK•3 days agoSarepta Therapeutics spikes 57% after a key trial shows its experimental gene therapy worked in 3 patients (SRPT, SLDB)
Sarepta Therapeutics was up more than 57% Tuesday morning after a key trial showed its experimental gene therapy worked in three patients. Follow Sarepta Therapeutics in real time here. Sarepta on Tuesday announced positive results for an early trial of three patients with duchenne muscular dystrophy who were given a gene therapy. After receiving the therapy, three boys, under the age of six, saw an increase in the protein.
- Business Insider UK•3 days ago
Sarepta stock soars as early-stage gene therapy data shows promise
(Reuters) - Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company's shares up 60 percent.
- Business Insider UK•3 days ago
Sarepta stock soars as early-stage gene therapy data shows promise
(Reuters) - Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company's shares up 60 percent.
- CNBC•3 days ago
Sarepta Therapeutics shares soar 50% on positive preliminary results for muscular dystrophy gene therapy
Sarepta shared results from three children who received the gene therapy in a clinical trial.
- Forbes•3 days ago
A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients
An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.
- Zacks•7 days ago
Options Traders Expect Huge Moves in Sarepta (SRPT) Stock
Sarepta (SRPT) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•8 days ago
Sarepta Inks Manufacturing Deal for Gene Therapy Program
Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.
- Zacks•16 days ago
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Motley Fool•18 days ago3 Stocks That Tripled in Just 12 Months
Can these red-hot companies keep up the pace?
- MarketWatch•21 days ago
Sarepta receives negative opinion in Europe for treatment for Duchenne muscular dystrophy
Sarepta Therapeutics Inc. said Friday it has received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its Exondys treatment for the rare disease Duchenne muscular dystrophy. The company had already said on its May 5 earnings call that it expected the negative opinion. Sarepta said it will now ask for a re-examination of the opinion, which would result in the assignment of a new rapporteur and co-rapporteur.
